A meta-analysis based on data from 2208 patients with cancer showed that high MCL1 expression was frequently observed in patients with poorly differentiated digestive system tumors or lung adenocarcinoma, and higher MCL1 expression was associated with overall shorter survival in patients with hematological and digestive system tumors or with lung cancer. This evidence concerns the gene MCL1 and lung adenocarcinoma.